Author details

Full Name

David M Holtzman

Affiliation

ORCID

Career Start Year

1969

Papers

681

H Index

165

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37610059	Mapping sleep's oscillatory events as a biomarker of Alzheimer's disease.	Alzheimers Dement	2024
36975407	Independent study demonstrates amyloid probability score accurately indicates amyloid pathology.		2023
36368315	TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.	Neuron	2023
36219197	Chronic TREM2 activation exacerbates AÎ²-associated tau seeding and spreading.	Journal of Experimental Medicine	2023
35934777	Using Alzheimer's disease blood tests to accelerate clinical trial enrollment.	Alzheimers Dement	2023
37939161	Current status of amyloid-targeting immunotherapies for Alzheimer's disease.		2023
37749326	APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFÎ²-mediated checkpoints.	Nat Immunol	2023
37667136	Emerging diagnostics and therapeutics for Alzheimer disease.		2023
37735240	The VCAM1-ApoE pathway directs microglial chemotaxis and alleviates Alzheimer's disease pathology.		2023
37732218	Chronotype is Associated with Sleep Quality in Older Adults.	medRxiv	2023
37732214	Tauopathy severely disrupts homeostatic set-points in emergent neural dynamics but not in the activity of individual neurons.		2023
37995685	Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist.		2023
37645718	APOE2 gene therapy reduces amyloid deposition, and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease.	bioRxiv	2023
37577565	Cell autonomous role of border associated macrophages in ApoE4 neurovascular dysfunction and susceptibility to white matter injury.		2023
38086389	APOE3ch alters microglial response and suppresses AÎ²-induced tau seeding and spread.		2023
37562846	Parenchymal border macrophages regulate tau pathology and tau-mediated neurodegeneration.	Life Sci Alliance	2023
37289593	Standardized immunoprecipitation protocol for efficient isolation of native apolipoprotein E particles utilizing HJ15.4 monoclonal antibody.		2023
37279069	APOE-Îµ4 synergizes with sleep disruption to accelerate AÎ² deposition and AÎ²-associated tau seeding and spreading.		2023
36824720	Mapping Sleep's Oscillatory Events as a Biomarker of Alzheimer's Disease.	bioRxiv	2023
37142785	Author Correction: Apolipoprotein E controls cerebrovascular integrity via cyclophilin A.		2023
36890231	Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy.	Nature	2023
37016433	Insights from new in vivo models of TREM2 variants.		2023
37072097	Apolipoprotein E O-glycosylation is associated with amyloid plaques and APOE genotype.		2023
36634180	ApoE isoform- and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy.	Science	2023
37129980	KATP channels are necessary for glucose-dependent increases in amyloid-Î² and Alzheimer's disease-related pathology.		2023
37443334	CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease.	Nat Med	2023
37315112	Gut microbiome composition may be an indicator of preclinical Alzheimer's disease.	Sci Transl Med	2023
36803602	Hallmarks of neurodegenerative diseases.		2023
36798327	ApoE Alzheimer's Disease AÎ²-amyloid plaque morphology varies according to APOE isotype.	Res Sq	2023
36542469	Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression.	Brain	2023
37172094	TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma.		2023
36922879	Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy.		2023
36919987	Lecanamab Ushers in a New Era of Anti-Amyloid Therapy for Alzheimer's Disease.	Ann Neurol	2023
37292658	Endogenous recapitulation of Alzheimer's disease neuropathology through human 3D direct neuronal reprogramming.	bioRxiv	2023
37099634	Sleep deprivation exacerbates microglial reactivity and AÎ² deposition in a -dependent manner in mice.		2023
35285073	APOE Antibody Inhibits AÎ²-Associated Tau Seeding and Spreading in a Mouse Model.	Annals of Neurology	2022
36183195	Comparison of plasma and CSF biomarkers in predicting cognitive decline.	Ann Clin Transl Neurol	2022
36306735	TREM2 drives microglia response to amyloid-Î² via SYK-dependent and -independent pathways.	Cell	2022
35446396	Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment.	JAMA network open	2022
36351425	Emerging roles of innate and adaptive immunity in Alzheimer's disease.	Immunity	2022
35750033	Cholesterol and matrisome pathways dysregulated in astrocytes and microglia.	Cell	2022
35941704	Corpora amylacea are associated with tau burden and cognitive status in Alzheimer's disease.	Acta Neuropathol Commun	2022
35867858	Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.	Brain	2022
36329501	Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-Î²42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.	Molecular Neurodegeneration	2022
35358703	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease.	Neurobiol Dis	2022
36056345	LRP1 is a neuronal receptor for Î±-synuclein uptake and spread.	Mol Neurodegener	2022
36383681	APOE Îµ4 genotype, amyloid-Î², and sex interact to predict tau in regions of high APOE mRNA expression.	Sci Transl Med	2022
35977543	Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma.	Immunity	2022
35659876	Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neurons.	Cell Stem Cell	2022
34002449	Network dysfunction in cognitively normal APOE Îµ4 carriers is related to subclinical tau.	Alzheimers Dement	2022